Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit - PubMed (original) (raw)
Multicenter Study
Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit
Christopher R Frei et al. Clin Ther. 2010 Feb.
Abstract
Objective: This study evaluated the survival benefit of US community-acquired pneumonia (CAP) practice guidelines in the intensive care unit (ICU) setting.
Methods: We conducted a retrospective cohort study of adult patients with CAP who were admitted to 5 community hospital ICUs between November 1, 1999, and April 30, 2000. The guidelines for antibiotic prescriptions were the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Guideline-concordant antimicrobial therapy was defined as a beta-lactam plus fluoroquinolone or macrolide, antipseudomonal beta-lactam plus fluoroquinolone, or antipseudomonal beta-lactam plus aminoglycoside plus fluoroquinolone or macrolide. Patients with a documented beta-lactam allergy were considered to have received guideline-concordant therapy if they received a fluoroquinolone with or without clindamycin, or aztreonam plus fluoroquinolone with or without aminoglycoside. All other antibiotic regimens were considered to be guideline discordant. Time to clinical stability, time to oral antibiotics, length of hospital stay, and in-hospital mortality were evaluated with regression models that included the outcome as the dependent variable, guideline-concordant antibiotic therapy as the independent variable, and the Pneumonia Severity Index (PSI) score and facility as covariates.
Results: The median age of the 129 patients included in the study was 71 years (interquartile range, 60-79 years). Sixty-two of 129 patients (48%) were male. Comorbidities included liver dysfunction (7 patients [5%]), heart failure (62 [48%]), renal dysfunction (39 [30%]), cerebrovascular disease (21 [16%]), and cancer (14 [11%]). The median (25th-75th percentile) PSI score was 119 (98-142), and overall mortality was 19% (25 patients). Patient demographics were similar between groups. Fifty-three patients (41%) received guideline-endorsed therapies. Guideline-discordant therapy was associated with an increase in inpatient mortality (25% vs 11%; odds ratio = 2.99 [95% CI, 1.08-9.54]). Receipt of guideline-concordant antibiotics was not associated with reductions in time to clinical stability, time to oral antibiotics, or length of hospital stay when patients who died were excluded from the analysis.
Conclusion: Guideline-concordant empiric antibiotic therapy was associated with improved survival among these patients with CAP who were admitted to 5 ICUs.
Copyright 2010. Published by EM Inc USA.
Similar articles
- Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Frei CR, et al. Am J Med. 2006 Oct;119(10):865-71. doi: 10.1016/j.amjmed.2006.02.014. Am J Med. 2006. PMID: 17000218 - Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules.
McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. McCabe C, et al. Arch Intern Med. 2009 Sep 14;169(16):1525-31. doi: 10.1001/archinternmed.2009.259. Arch Intern Med. 2009. PMID: 19752411 - Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia.
Mortensen EM, Restrepo M, Anzueto A, Pugh J. Mortensen EM, et al. Am J Med. 2004 Nov 15;117(10):726-31. doi: 10.1016/j.amjmed.2004.06.028. Am J Med. 2004. PMID: 15541321 - Community-acquired pneumonia in the elderly.
Fung HB, Monteagudo-Chu MO. Fung HB, et al. Am J Geriatr Pharmacother. 2010 Feb;8(1):47-62. doi: 10.1016/j.amjopharm.2010.01.003. Am J Geriatr Pharmacother. 2010. PMID: 20226392 Review. - The role of new therapies for severe community-acquired pneumonia.
Restrepo MI, Anzueto A. Restrepo MI, et al. Curr Opin Infect Dis. 2006 Dec;19(6):557-64. doi: 10.1097/QCO.0b013e3280106b7f. Curr Opin Infect Dis. 2006. PMID: 17075331 Review.
Cited by
- Non-adherence to antimicrobial treatment guidelines results in more broad-spectrum but not more appropriate therapy.
van der Velden LB, Tromp M, Bleeker-Rovers CP, Hulscher M, Kullberg BJ, Mouton JW, Sturm PD, Pickkers P. van der Velden LB, et al. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1561-8. doi: 10.1007/s10096-011-1478-5. Epub 2011 Nov 23. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22108843 Free PMC article. - Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis.
Troitino AX, Porhomayon J, El-Solh AA. Troitino AX, et al. Lung. 2013 Jun;191(3):229-37. doi: 10.1007/s00408-013-9462-8. Epub 2013 Apr 10. Lung. 2013. PMID: 23572322 Review. - Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Rahmel T, Asmussen S, Karlik J, Steinmann J, Adamzik M, Peters J. Rahmel T, et al. BMC Anesthesiol. 2017 Jun 14;17(1):78. doi: 10.1186/s12871-017-0376-5. BMC Anesthesiol. 2017. PMID: 28615012 Free PMC article. - Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence.
Spoorenberg V, Prins JM, Stobberingh EE, Hulscher ME, Geerlings SE. Spoorenberg V, et al. Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1545-56. doi: 10.1007/s10096-013-1909-6. Epub 2013 Jul 4. Eur J Clin Microbiol Infect Dis. 2013. PMID: 24213913 Clinical Trial. - Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study.
Frei CR, Mortensen EM, Copeland LA, Attridge RT, Pugh MJ, Restrepo MI, Anzueto A, Nakashima B, Fine MJ. Frei CR, et al. BMC Health Serv Res. 2010 May 27;10:143. doi: 10.1186/1472-6963-10-143. BMC Health Serv Res. 2010. PMID: 20507628 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous